A model for markers and latent health status

Journal of the Royal Statistical Society. Series B: Statistical Methodology

Volumn 62, Issue 4, 2000, Pages 747-762

  Lee, Mei Ling Ting ^a,b,c,d   DeGruttola, Victor ^d   Schoenfeld, David ^b,c,d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Acquired immune deficiency syndrome; Bivariate Wiener process; Disease progression; Health status; Latent process; Marker; Prediction; Proportional hazards; Survival analysis

Indexed keywords

EID: 0034354041     PISSN: 13697412     EISSN: None     Source Type: Journal    
DOI: 10.1111/1467-9868.00261     Document Type: Article

References (16)

1. Berman, S. M. (1990) A stochastic model for the distribution of HIV latency times based on T4 counts. Biometrika, 77, 733-741.
2. - (1994) Perturbation of normal random vectors by nonnormal translations, and application to HIV latency time distributions. Ann. Appl. Probab., 4, 968-980.
3. DeGruttola, V., Beckett, L., Coombs, R., Arduino, J. M., Balfour. H., Rasheed, S., Hollinger, F. B., Fischl, M. A. and Volberding, P. (1994) Serum p24 antigen levels as an intermediate end point in clinical trials of zidovudine in people infected with the human immunodeficiency virus type I, (HIV-1). J. Infect. Dis., 169, 713-721.
4. Doksum, K. and Hoyland, A. (1992) Models for variable-stress accelerated testing experiments based on Wiener processes and the inverse Gaussian distribution. Technometrics, 34, 74-82.
5. Doksum, K. A. and Normand, S.-L. (1995) Gaussian models for degradation processes - part I: Methods for the analysis of biomarker data. Lifetime Data Anal., 1, 131-144.
6. Dolin, R., Amato, D. A., Fischl, M. A., Pettinelli, C., Beltangady, M., Liou, S., Brown, M. J., Cross, A. P., Hirsch, M. S., Hardy, W. D., Mildva, D., Blair, D. C., Powderly, W. G., Para, M. F., Fife, K. H., Steigbigel, R. T., Smaldone, L. and the AIDS Clinical Trial Group (1995) Zidovudine compared with didanosine in patients with advanced HIV type 1 infection and little or no previous experience with zidovudine. Arch. Intern. Med., 155, 961-974.
7. Jewell, N. P. and Kalbfleisch, J. D. (1996) Marker processes in survival analysis. Lifetime Data Anal., 1, 15-29.
8. Jewell, N. P. and Nielsen, J. P. (1993) A framework for consistent prediction rules based on markers. Biometrikam 80, 153-164.
9. Lu, J. (1995) A reliability model based on degradation and lifetime data. PhD Thesis. McGill University. Montreal.
10. Prentice, R. L. (1989) Surrogate endpoints in clinical trials: definition and operational criteria. Statist. Med., 8 431-440.
11. Shi, M., Taylor, J. M. G. and Munoz, A. (1996) Models for residual time to AIDS. Lifetime Data Anal., 2, 31-49.
12. Whitmore, G. A. (1975) The inverse Gaussian distribution as a model of hospital stay. Hlth Serv. Res., 10, 297-302.
13. - (1979) An inverse Gaussian model for labour turnover. J. R. Statist. Soc. A, 142, 468-478.
14. - (1995) Estimating degradation by a Wiener diffusion process subject to measurement error. Lifetime Data Anal., 1, 307-319.
15. Whitmore, G. A., Crowder, M. J. and Lawless, J. F. (1998) Failure inference from a marker process based on a bivariate Wiener model. Lifetime Data Anal., 4, 229-251.
16. Whitmore, G. A. and Schenkelberg, F. (1997) Modelling accelerated degradation data using Wiener diffusion with a time scale transformation. Lifetime Data Anal., 3, 1-19.